Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Célèste Lebbé(Inserm), Antoîne Italiano(Université de Bordeaux), Nadine Houédé(Institut de Cancérologie de Bourgogne), Ahmad Awada(Université Libre de Bruxelles), Philippe Aftimos(Université Libre de Bruxelles), Thierry Lesimple(Centre Eugène Marquis), Monica Dinulescu(Centre Hospitalier Universitaire de Rennes), Jan H.M. Schellens(The Netherlands Cancer Institute), Suzanne Leijen(The Netherlands Cancer Institute), Sylvie Rottey(Ghent University Hospital), Vibeke Krüse(Ghent University Hospital), Richard Kefford(Westmead Hospital), Éric Raymond(Hôpital Saint Joseph), Sandrine Faivre(Hôpital Beaujon), Céline Pagès(Inserm), Carlos Gomez‐Roca(Institut universitaire du cancer de Toulouse Oncopole), Armin Schueler(Merck KGaA, Darmstadt (Germany)), Samantha Goodstal(Merck KGaA, Darmstadt (Germany)), Giorgio Massimini(Merck KGaA, Darmstadt (Germany)), Jean-Pierre Delord(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 14
Abstract
Related Papers
No related papers found
Powered by citation graph analysis